Global HIV Diagnostics Market to Breach USD 3422.08 million by 2021
Posted by rohan on September 22nd, 2017
The Global HIV Diagnostics Market was worth USD 2173.80 million in 2016 and estimated to be growing at a CAGR of 9.5%, to reach USD 3422.08 million by 2021. The human immunodeficiency Virus (HIV) infection refers to a kind of retrovirus that causes (AIDS). HIV affects some immune cells and it weakens immune system bringing about loss of capacity to fight against the organisms that causes diseases.
HIV spreads through exchange of fluids with some infected individual, for example, blood exchange or imparting needles to somebody who is HIV contaminated. Additionally, HIV can spread from infected mother to child during pregnancy. Here are some of the symptoms of HIV disease are slight fever, weakness, swollen glands, cerebral pains and muscle hurts. The present situation is like various POC/rapid tests are under clinical advancement and examination in the item pipelines of significant market members and are relied upon to acquire regulatory approval in various local segments of the market. This normal increment in the quantity of item offerings to the worldwide market space is required to fuel the development of the HIV diagnostics industry over the forecast period.
Major factors driving the market are, the technological advancement of disease diagnostic tests, and the foreseen improvement and commercialization of novel, regulatory authorities approved POC and rapid CD4, p24 antigen and EID tests; it is expected that all the major regional market segments will witness an expansion in market demand over the forecast period. There is a need to increase in introducing easily accessible, efficient robust diagnostics tests. Because of the financial resource constrained settings in a huge share of the disease affected regions it is as yet not feasible to perform the current, complex screening, staging and monitoring tests. This is either because of the absence of adequate testing labs or an absence of prepared clinical technicians capable of performing the tests. These limitations of laboratory based testing are a catalyst to the improvement of convenient and simple to execute point of care, rapid tests.
Free sample of the report is available @ http://www.marketdataforecast.com/market-reports/global-hiv-diagnostics-market-2136/request-sample
The Global HIV Diagnostics Market is segmented on the basis of Product, Type, End-User and geography. Based on product, market is segmented into Consumables (Assays and Kits & Reagents, Other consumables), Instruments, Software & Services]. Based on Type, market is segmented into Antibody Tests, HIV-2 & Group O Diagnostic Tests, Viral Identification Tests, CD4 Testing, Viral load testing, Early Infant Diagnostics. Further on the basis of Antibody tests market is segmented into (HIV-1 Screening tests- Elisa/EIA, Rapid Tests, Home Access Dried blood spots), (HIV-1 Antibody Confirmatory Tests- Western Blot Test, Indirect immunofluorescence Assays(IFA), Line immunoassays(Cnf), Radio immunoprecipitation Assays(RIPA)). Based on HIV-2 & Group O Diagnostic Tests market is further dived into Blood Antibody Tests, DBS Tests, and Line ImmunoAssay (HIV-2) and based on Viral Identification Tests, market is divided into p24 Antigen Test, Qualitative PCR Tests, and Viral Culture.
On the basis of geography, the global market is analysed under various regions namely North America, Europe, Asia-Pacific and Rest of the World. HIV Diagnostics Market was dominated by North America, with the overall market share of over 38% globally. North America was followed by Asia pacific. Asia Pacific is predicted to grow at a rapid pace in the coming few years, because of its high unmet demand in India and China.
Major players in the market are Abbott Healthcare, Alere Inc., Brsitol-Myers Squibb, Abbvie Inc., Gilead Sciences, Janssen Therapeutics, Merck & Co. Inc, BD Biosciences, VIIV Healthcare, Beckman Coulter, Partec, Sysmex, Apogee Flow Systems, Zyomyx Inc., Mylan inc., PointCare Technologies Inc., Roche Diagnostics, Qiagen, Siemens Healthcare, and bioMerieux dominated HIV diagnostics market share in 2014.
Like it? Share it!
About the Authorrohan
Joined: September 20th, 2017
Articles Posted: 1,346
More by this author